Author:
Chen Hengyi,Yao Wenxiu,Chu Qian,Han Rui,Wang Yubo,Sun Jianguo,Wang Dong,Wang Yongsheng,Cao Mengshu,He Yong
Reference39 articles.
1. Cancer statistics, 2014;Siegel;CA Cancer J. Clin,2014
2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med,2009
3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012
4. Non-small cell lung cancer, version 1;Ettinger;J. Natl Compr. Canc. Netw,2015
5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献